Aura Biosciences (AURA) Net Income towards Common Stockholders (2020 - 2026)

Aura Biosciences has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$33.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 22.56% year-over-year to -$33.7 million; the trailing twelve-month figure through Mar 2026 stood at -$112.4 million (down 19.46% YoY), and the FY2025 full-year result was -$106.2 million, down 23.05% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$33.7 million, down from -$25.6 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$12.8 million in Q1 2022, with the low at -$33.7 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$21.3 million across 5 years, with a median of -$20.3 million in 2024.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 116.15% — and 2025, when it decreased 1.35%.
• Aura Biosciences' Net Income towards Common Stockholders stood at -$17.6 million in 2022, then declined by 25.65% to -$22.1 million in 2023, then decreased by 13.92% to -$25.2 million in 2024, then declined by 1.35% to -$25.6 million in 2025, then sank by 31.83% to -$33.7 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$33.7 million (Q1 2026), -$25.6 million (Q4 2025), and -$26.1 million (Q3 2025), per Business Quant data.